Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

soundsgood02 124 posts  |  Last Activity: 12 hours ago Member since: Jul 26, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    TBIO at the present time.....

    by retiredceo2002 Apr 23, 2015 12:08 PM
    soundsgood02 soundsgood02 12 hours ago Flag

    ..Quite crowded place...In a marketplace that are ready to explode...

  • Reply to

    TBIO at the present time.....

    by retiredceo2002 Apr 23, 2015 12:08 PM
    soundsgood02 soundsgood02 14 hours ago Flag

    Who are the big boys in liquid biopsy?

  • Reply to

    TBIO at the present time.....

    by retiredceo2002 Apr 23, 2015 12:08 PM
    soundsgood02 soundsgood02 Apr 23, 2015 5:26 PM Flag

    ...Some liquid biopsy stock will be for sure the buy of a lifetime...TBIO is completely undiscovered as liquid biopsy stock...Maybe some other news will change this situation...A FDA update announced in the CC for the next few days... TBIO is ice cold at the present time...

    Sentiment: Buy

  • soundsgood02 by soundsgood02 Apr 23, 2015 4:16 AM Flag

    CAMBRIDGE, UK, and OMAHA, NE, USA (April, 23, 2015) --Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCRTM (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.

    Sentiment: Strong Buy

  • Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits -

    Sentiment: Strong Buy

  • soundsgood02 soundsgood02 Apr 22, 2015 4:38 PM Flag

    ddPCR...Don't seem to be Trov test...

  • soundsgood02 soundsgood02 Apr 22, 2015 1:42 PM Flag

    Just for information... Not Bioc study..
    In this study, urine samples were taken from patients with metastatic NSCLC who progressed on erlotinib treatment and ctDNA was extracted by a method that preferentially isolates short, fragmented ctDNA. Droplet digital polymerase chain reaction (ddPCR) was used to quantify the ctDNA and yielded an average of total amplifiable ctDNA per sample of 0.4 µg (range, 0.04 to 2.4 µg). Spiked cell lines were used for analytical characterisation and demonstrated that the EGFR T790M assay had a lower limit of detection of two copies within a background of 60 ng of wild-type DNA, yielding an analytical sensitivity of 0.01%.

  • Reply to

    TBIO AACR 22 apr

    by soundsgood02 Apr 21, 2015 8:28 AM
    soundsgood02 soundsgood02 Apr 21, 2015 8:40 AM Flag

    Multiplexed ICE COLD-PCR coupled to NGS and ddPCR enables enhanced detection of low-level DNA mutations in tissues and liquid biopsies
    Presentation Time: Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
    Location: Section 31
    Poster Board Number: 20
    Author Block: Katherine Anne Richardson1, Sarah Statt1, Grant Wu1, Karissa Scott1, Erin Montagne1, Sheena Jensen1, Courtney Cubrich1, Phil Krzycki1, Jason Stoddard1, Amy Kruempel1, Emily McCutchen1, Stephanie Veys1, Kylee Baughman1, Sarah Cherubin1, Vicki Rosendale1, Jaclyn Pope1, Paula Bartlett1, Phil Eastlake2, Stephanie Peterson1, Benjamin Legendre, Jr.1. 1Transgenomic, Inc., Omaha, NE; 2Transgenomic, Ltd, Glasgow, United Kingdom
    Abstract Body: Introduction: The use of “liquid biopsies”, where limited or no tumor tissue is available, is increasingly important for molecular demographics, diagnostics and pharmacodynamic monitoring of patients during therapy.
    The ICE COLD-PCR (ICP) technique preferentially amplifies sequence alterations in samples having either vast excesses of wild-type sequence or when sample DNA quantity is sub-optimal. ICP delivers unbiased, high-level enrichment of gene regions enabling determination of point mutations and insertions/deletions using Sanger sequencing, Next Generation Sequencing (NGS) or droplet digital PCR (ddPCR). This is especially important when sample DNA, e.g. from circulating free DNA, exosomes and circulating tumor cells (CTCs), is insufficient for multiplexed analysis.
    A critical limitation of mutational analysis of such samples is the need for increasing amounts of DNA for detecting very low-level mutations. A range of 100 to330 ng of substrate DNA is usually needed for reliable detection of alterations present at 0.01% in the sample DNA; this is not feasible with the limited quantities of blood/plasma/serum from clinical trials. ICP’s ability to enrich alterations can provide a ≥100-fold increase in Sanger, NGS and ddPCR sensitivity.
    Materials and Methods: To increase throughput, address the limiting amounts of DNA present in these samples and provide enriched amplification from many different gene regions in a single DNA sample, a multiplex ICP approach has been developed (MX-ICP). This MX-ICP method provides enrichment of any alteration present in all targeted genes from a single sample of DNA. When MX-ICP products are analyzed by Sanger, NGS or ddPCR, lower quantities of sample DNA can be used for detection of mutations at ≤0.01%.
    We compared detection of low-level of mutations in limiting amounts of DNA, with or without the use of MX-ICP prior to NGS and ddPCR, using digitally verified chromosomal DNA mixtures from Horizon Diagnostics. The alterations analyzed were from (1) CTC and NSCLC patients’ plasma, (2) longitudinal sampling of melanoma patients and (3) CTCs isolated from NSCLC patients. In all cases, use of MX-ICP, prior to analysis using NGS or ddPCR, enabled very sensitive detection with low amounts of input DNA.
    Conclusion: MX-ICP is a key component of procedures for sensitive detection and monitoring of genetic alterations in multiple targets using a single DNA sample. Coupling MX-ICP with platforms such as NGS and ddPCR enables the use of these powerful technologies for high sensitivity detection and monitoring of liquid biopsies from cancer patients. The combination of MX-ICP with NGS and ddPCR platforms means that they can be used efficiently for detection of alterations at
    ≤0.01% in samples with

  • Reply to

    TBIO AACR 22 apr

    by soundsgood02 Apr 21, 2015 8:28 AM
    soundsgood02 soundsgood02 Apr 21, 2015 8:29 AM Flag

    A critical limitation of mutational analysis of such samples is the need for increasing amounts of DNA for detecting very low-level mutations. A range of 100 to330 ng of substrate DNA is usually needed for reliable detection of alterations present at 0.01% in the sample DNA; this is not feasible with the limited quantities of blood/plasma/serum from clinical trials. ICP’s ability to enrich alterations can provide a ≥100-fold increase in Sanger, NGS and ddPCR sensitivity.
    Materials and Methods: To increase throughput, address the limiting amounts of DNA present in these samples and provide enriched amplification from many different gene regions in a single DNA sample, a multiplex ICP approach has been developed (MX-ICP). This MX-ICP method provides enrichment of any alteration present in all targeted genes from a single sample of DNA. When MX-ICP products are analyzed by Sanger, NGS or ddPCR, lower quantities of sample DNA can be used for detection of mutations at ≤0.01%.
    We compared detection of low-level of mutations in limiting amounts of DNA, with or without the use of MX-ICP prior to NGS and ddPCR, using digitally verified chromosomal DNA mixtures from Horizon Diagnostics. The alterations analyzed were from (1) CTC and NSCLC patients’ plasma, (2) longitudinal sampling of melanoma patients and (3) CTCs isolated from NSCLC patients. In all cases, use of MX-ICP, prior to analysis using NGS or ddPCR, enabled very sensitive detection with low amounts of input DNA.
    Conclusion: MX-ICP is a key component of procedures for sensitive detection and monitoring of genetic alterations in multiple targets using a single DNA sample. Coupling MX-ICP with platforms such as NGS and ddPCR enables the use of these powerful technologies for high sensitivity detection and monitoring of liquid biopsies from cancer patients. The combination of MX-ICP with NGS and ddPCR platforms means that they can be used efficiently for detection of alterations at
    ≤0.01% in samples with

  • soundsgood02 by soundsgood02 Apr 21, 2015 8:28 AM Flag

    Abstract Number: 5438
    Presentation Title: Multiplexed ICE COLD-PCR coupled to NGS and ddPCR enables enhanced detection of low-level DNA mutations in tissues and liquid biopsies
    Presentation Time: Wednesday, Apr 22, 2015, 8:00 AM -12:00 PM
    Location: Section 31
    Poster Board Number: 20
    Author Block: Katherine Anne Richardson1, Sarah Statt1, Grant Wu1, Karissa Scott1, Erin Montagne1, Sheena Jensen1, Courtney Cubrich1, Phil Krzycki1, Jason Stoddard1, Amy Kruempel1, Emily McCutchen1, Stephanie Veys1, Kylee Baughman1, Sarah Cherubin1, Vicki Rosendale1, Jaclyn Pope1, Paula Bartlett1, Phil Eastlake2, Stephanie Peterson1, Benjamin Legendre, Jr.1. 1Transgenomic, Inc., Omaha, NE; 2Transgenomic, Ltd, Glasgow, United Kingdom

    Abstract Body: Introduction: The use of “liquid biopsies”, where limited or no tumor tissue is available, is increasingly important for molecular demographics, diagnostics and pharmacodynamic monitoring of patients during therapy.
    The ICE COLD-PCR (ICP) technique preferentially amplifies sequence alterations in samples having either vast excesses of wild-type sequence or when sample DNA quantity is sub-optimal. ICP delivers unbiased, high-level enrichment of gene regions enabling determination of point mutations and insertions/deletions using Sanger sequencing, Next Generation Sequencing (NGS) or droplet digital PCR (ddPCR). This is especially important when sample DNA, e.g. from circulating free DNA, exosomes and circulating tumor cells (CTCs), is insufficient for multiplexed analysis.

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 17, 2015 1:09 PM Flag

    Trigger event is approaching...

    Sentiment: Buy

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 15, 2015 5:02 PM Flag

    No significant news..No stock or house upgrade...10k filed ...

    Sentiment: Hold

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 15, 2015 1:58 PM Flag

    ...With 7 millions raised 1 month ago and a very recent deal with the lenders to waive default...?

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 14, 2015 6:20 PM Flag

    Tomorrow they could announce the first ice cold pcr trigger event...

    Sentiment: Buy

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 14, 2015 6:51 AM Flag

    2 days...Some update Has to come...

    Sentiment: Hold

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 10, 2015 9:47 AM Flag

    ...The sector of liquid biopsy is ready to explode...According to the last presentation Icecold-Pcr seems the right product in the right time...Little delay of the lunch and of annual report don't help the price in this moment...

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 9, 2015 5:46 PM Flag

    ...Meanwhile the market is discounting very negative trigger event...Next week...Boom or bust...

    Sentiment: Hold

  • Reply to

    TRIGGER EVENT...

    by soundsgood02 Apr 2, 2015 5:42 PM
    soundsgood02 soundsgood02 Apr 3, 2015 1:20 PM Flag

    ...The new loan agreement demonstrate that ICE-COLD PCR is ready to be launched.. It's clear the Lenders' (and Biggest shareholders )optimism about this launch...

    (h) Section 14.1 of the Loan Agreement is amended by inserting the following new definition in the correct alphabetical order:



    ““ ICE COLD Excess Proceeds ” has the meaning set forth in the definition of ICE COLD Trigger Event.



    “ ICE COLD Sale ” means any transaction or series of related transactions involving the execution and delivery by Borrower of any licensing agreements, sale agreements or other similar commercial transactions, arrangements or agreements with respect to the product line commonly known as ICE COLD PCR.



    “ ICE COLD Trigger Event ” means receipt by Borrower of net cash proceeds in respect of all ICE COLD Sales, taken together, in excess of $10,000,000 in the aggregate (the amount of aggregate net cash proceeds in excess of $10,000,000 being referred to as the “ ICE COLD Excess Proceeds ”). For the avoidance of doubt, after the occurrence of the first ICE COLD Trigger Event, each subsequent ICE COLD Sale shall result in an ICE COLD Trigger Event.”

  • soundsgood02 by soundsgood02 Apr 2, 2015 5:42 PM Flag

    Randal J.Kirk wait a series of Trigger Events about ICE COLD PCR...

  • Reply to

    What about the delayed 10K?

    by culleraa Apr 1, 2015 3:03 PM
    soundsgood02 soundsgood02 Apr 1, 2015 4:24 PM Flag

    15 days extension...

PRAN
1.13+0.01(+0.89%)Apr 24 4:00 PMEDT